NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹0.62 Cr | ₹0.44 Cr | ₹0.10 Cr | ₹0.28 Cr | ₹0.28 Cr |
What is the latest Contingent Liabilities ratio of NGL FINECHEM ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹0.62 Cr |
| Mar2024 | ₹0.44 Cr |
| Mar2023 | ₹0.10 Cr |
| Mar2022 | ₹0.28 Cr |
| Mar2021 | ₹0.28 Cr |
How is Contingent Liabilities of NGL FINECHEM Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.62 Cr | 40.59 | |
| Mar2024 | ₹0.44 Cr | 336.63 | |
| Mar2023 | ₹0.10 Cr | -63.67 | |
| Mar2022 | ₹0.28 Cr | 0.00 | |
| Mar2021 | ₹0.28 Cr | - | |
Compare Contingent Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹944.7 Cr | 1.2% | 0.2% | -14.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹401,541.0 Cr | -3.5% | -6.4% | -2.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,031.0 Cr | -5.8% | -1.6% | 10.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹138,451.0 Cr | 1.4% | 7% | 23.7% | Stock Analytics | |
| CIPLA | ₹112,377.0 Cr | -4.7% | -6.8% | -0.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,355.5 Cr | -2.8% | -8.1% | -11.1% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 1.2% |
0.2% |
-14.8% |
| SENSEX | -0.4% |
-1.7% |
9.1% |
You may also like the below Video Courses